Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib

Three-year follow-up of ibrutinib in CLL demonstrated continued activity with durable responses that improve in quality with extended treatment. Toxicity diminished over time with respect to grade